Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

Leuk Lymphoma. 2022 Jan;63(1):243-246. doi: 10.1080/10428194.2021.1971224. Epub 2021 Aug 26.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Humans
  • Immunoconjugates* / therapeutic use
  • Lymphoma, B-Cell* / diagnosis
  • Lymphoma, B-Cell* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Treatment Outcome

Substances

  • Immunoconjugates